The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews
Open accessAbstract
Objective: To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities. Design: Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastatic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms. Subjects: 81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer. Main outcome measure: Survival threshold for accepting chemotherapy. Results: The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy for a survival benefit of 1 week, while others would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life. Conclusions: Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely. Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
On the Elicitation of Preferences for Alternative Therapies
McNeil, B. J., Pauker, S. G., Sox, H. C., & Tversky, A. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205273062103 · Cited by 1,668
Slevin, M. L., Stubbs, L., Plant, H. J., Wilson, P., Gregory, W. M., Armes, P. J., & Downer, S. M. (1990) · BMJ · doi:10.1136/bmj.300.6737.1458 · Cited by 753
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
Bernard, J. P., Souquet, P. J., Boissel, J. P., Chauvin, F., Cellerino, R., Tumarello, D., Cormier, Y., Ganz, P. A., Kaasa, S., Pater, J. L., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91882-m · Cited by 490
Incorporating Patients' Preferences into Medical Decisions
Kassirer, J. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302611 · Cited by 415
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Preferences for Health Outcomes: Comparison of Assessment Methods
Read, J. L., Quinn, R. J., Berwick, D. M., Fineberg, H. V., & Weinstein, M. C. (1984) · Medical Decision Making · doi:10.1177/0272989x8400400307 · Cited by 357
Age and Clinical Decision Making in Oncology Patients
Yellen, S. B., Cella, D. F., & Leslie, W. T. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.23.1766 · Cited by 354
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994) · Chest · doi:10.1378/chest.106.3.861 · Cited by 299
Methods for quality adjustment of life years
Nord, E. (1992) · Social Science & Medicine · doi:10.1016/0277-9536(92)90211-8 · Cited by 289
Stiggelbout, A. M., Kiebert, G. M., Kievit, J., Leer, J. W. H., Stoter, G., & De Haes, J. C. J. M. (1994) · Medical Decision Making · doi:10.1177/0272989x9401400110 · Cited by 175
McQuellon, R. P., Muss, H. B., Hoffman, S. L., Russell, G., Craven, B., & Yellen, S. B. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.858 · Cited by 161
Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.
Brundage, M., Davidson, J. R., & Mackillop, W. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.330 · Cited by 130
Richards, M., Ramirez, A. J., Degner, L. F., Fallowfield, L. J., Maher, E. J., & Neuberger, J. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00478-n · Cited by 65
(1995) · Lung Cancer · doi:10.1016/0169-5002(95)96410-w · Cited by 20
Cited by
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Temel, J. S., Greer, J. A., Admane, S., Gallagher, E. R., Jackson, V. A., Lynch, T. J., Lennes, I. T., Dahlin, C. M., & Pirl, W. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4459 · Cited by 696
Cullen, M. H., Billingham, L. J., Woodroffe, C. M., Chetiyawardana, A. D., Gower, N. H., Joshi, R., Ferry, D. R., Rudd, R. M., Spiro, S. G., Cook, J. E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3188 · Cited by 445
Health state utilities for non small cell lung cancer
Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., & Watkins, J. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-84 · Cited by 404
Matsuyama, R., Reddy, S., & Smith, T. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6236 · Cited by 403
Metadata
- Authors
- Silvestri, G., Pritchard, R., & Welch, H. G.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1998-09-19
- Volume
- 317
- Issue
- 7161
- Pages
- 771-775
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1968765750
- Cited by
- 433
- References
- 16
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.